A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck

Magnetic Resonance Materials in Physics, Biology and Medicine

Volumn 24, Issue 2, 2011, Pages 85-96

  Whitcher, Brandon ^a   Schmid, Volker J ^b   Collins, David J ^c   Orton, Matthew R ^c   Koh, Dow Mu ^c   De Corcuera, Isabela Diaz ^d   Parera, Marta ^d   Del Campo, Josep M ^d   Desouza, Nandita M ^c   Leach, Martin O ^c   Harrington, Kevin ^c   El Hariry, Iman A ^e  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bayesian; Gadolinium; Oncology; Perfusion; Permeability

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CONTRAST MEDIUM; LAPATINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BAYES THEOREM; BIOASSAY; BIOLOGICAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; HEAD AND NECK TUMOR; HUMAN; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BAYES THEOREM; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CONTRAST MEDIA; ENDPOINT DETERMINATION; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; TREATMENT OUTCOME;

EID: 79953309460     PISSN: 09685243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10334-010-0238-3     Document Type: Article

References (38)

1. DM Brizel RK Dodge RW Clough MW Dewhirst 1999 Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome Radiother and Oncol 53 2 113 117 10.1016/S0167-8140(99)00102-4 1:STN:280:DC%2BD3c7islGmsQ%3D%3D
2. K Lehtiö O Eskola T Viljanen T Grönoos L Sillanmäki R Grénman H Minn 2004 Imaging perfusion and hypoxia with PET to predict radiotherapy response in head and neck cancer Intern J Radiat Oncol Biol Phy 59 4 971 982 10.1016/j.ijrobp.2003.12.014 (Pubitemid 38834289)
3. Y Cao A Popovtzer D Li D Chepeha JS Moyer ME Prince F Worden T Teknos C Bradford SK Mukherji A Eisbruch 2008 Early prediction of outcome in advanced head and neck cancer based on tumour blood volume alterations during therapy: a prospective study Intern J Radiat Oncol Biol Phy 72 5 1287 1290 10.1016/j.ijrobp.2008.08.024
4. A Arora EM Scholar 2005 Role of tyrosine kinase inhibitors in cancer therapy J Pharm Exp Ther 315 3 971 979 10.1124/jpet.105.084145 1:CAS:528:DC%2BD2MXhtlalur3L (Pubitemid 41635382)
5. LJ Wilmes MG Pallavicini LM Fleming J Gibbs D Wang KL Li SC Partridge RG Henry DR Shalinsky D Hu-Lowe JW Park TM McShane Y Lu RC Brasch NM Hylton 2007 AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging Magn Reson Imaging 25 319 327 17371720 10.1016/j.mri.2006.09.041 1:CAS:528:DC%2BD2sXjtVagur0%3D (Pubitemid 46413652)
6. PM LoRusso SM Gadgeel A Wozniak AJ Barge HK Jones ZS DelProposto PA DeLuca JL Evelhoch SA Boerner C Wheeler 2008 Phase I evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors Invest New Drugs 26 159 167 18219445 10.1007/s10637-008-9112-9 1:CAS:528:DC%2BD1cXivFKnsLY%3D
7. J Ren Y Huan H Wang YJ Chang HT Zhao YL Ge Y Liu Y Yang 2008 Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis Clin Radiol 63 2 153 159 18194690 10.1016/j.crad.2007.07.023 1:STN:280:DC%2BD1c%2FktVKmug%3D%3D
8. L Ellis 2004 Epidermal growth factor receptor in tumor angiogenesis Hematol Oncol Clin North Am 18 1007 1021 15474332 10.1016/j.hoc.2004.06.002 (Pubitemid 39335756)
9. Clamp AR, Jayson GC (2008) The role of imaging in the clinical development of antiangiogenic agents. In: Teicher BA, Ellis LM (eds) Antiangiogenic agents in cancer therapy, cancer drug discovery and development, 2nd edn. Humana Press, Totowa, pp 525-536
10. MM Moasser LJ Wilmes CH Wong S Aliu KL Li D Wang YK Hom B Hann NM Hylton 2007 Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy J Magn Reson Imaging 26 6 1618 1625 17968965 10.1002/jmri.21196 (Pubitemid 350291291)
11. SM Noworolski NJ Fischbein MJ Kaplan Y Lu SJ Nelson L Carvajal RG Henry 2003 Challenges in dynamic contrast-enhanced MRI imaging of cervical lymph nodes to detect metastatic disease J Magn Reson Imaging 17 4 455 462 12655585 10.1002/jmri.10280 (Pubitemid 36396948)
12. J Asaumi Y Yanagi H Konouchi M Misatomi H Matsuzaki K Kishi 2004 Application of dynamic contrast-enhanced MRI to differentiate malignant lymphoma from squamous cell carcinoma in the head and neck Oral Oncol 40 579 584 15063385 10.1016/j.oraloncology.2003.12.002 (Pubitemid 38452677)
13. S Kim H Quon LA Loevner MA Rosen L Dougherty AM Kilger JD Glickson H Poptani 2007 Transcytolemmal water exchange in pharmacokinetic analysis of dynamic contrast-enhanced MRI data in squamous cell carcinoma of the head and neck J Magn Reson Imaging 26 6 1607 1617 17968962 10.1002/jmri.21207 (Pubitemid 350301150)
14. K Newbold I Castellano E Charles-Edwards D Mears A Sohaib M Leach P Rhys-Evans P Larke C Fisher K Harrington C Nutting 2009 An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computer tomography for detection of intratumoral hypoxia in head-and-neck cancer Intern J Radiat Oncol Biol Phys 74 1 29 37 10.1016/j.ijrobp.2008.07.039
15. CJ Juan CY Chen YM Jen HS Liu YJ Liu CJ Hsueh CY Wang YC Chou YT Chai GS Huang HW Chung 2009 Perfusion characteristics of late radiation injury of parotid glands: quantitative evaluation with dynamic contrast-enhanced MRI Europ Radiol 19 94 102 10.1007/s00330-008-1104-9
16. PJ Hoskin MI Saunders K Goodchild MEB Powell NJ Taylor H Baddeley 1999 Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer Br J Radiol 72 1093 1098 10700827 1:STN:280:DC%2BD3c7msFKmtg%3D%3D
17. M Rijpkema JHAM Kaanders FBM Joosten AJ van der Kogel A Heershap 2001 Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors J Magn Reson Imaging 14 4 457 463 11599071 10.1002/jmri.1207 1:STN:280:DC%2BD3MrkvFOjsw%3D%3D (Pubitemid 32906564)
18. VJ Schmid B Whitcher AR Padhani NJ Taylor GZ Yang 2009 A Bayesian hierarchical model for the analysis of a longitudinal dynamic contrast-enhanced MRI oncology study Magn Reson Med 61 1 163 174 19097226 10.1002/mrm.21807
19. SS Kety 1951 The theory and applications of the exchange of inert gas at the lungs and tissues Pharm Rev 3 1 41 14833874 1:CAS:528:DyaG3MXjtVGgug%3D%3D
20. PS Tofts 1997 Modeling tracer kinetics in dynamic Gd-DTPA MR imaging J Magn Reson Imaging 7 91 101 9039598 10.1002/jmri.1880070113 1:STN:280: DyaK2s7ptFKmsA%3D%3D (Pubitemid 28365643)
21. 1-weighted DCE-MRI. In: Jackson A, Buckley DL, Parker GJM (eds) Dynamic contrast-enhanced magnetic resonance imaging in oncology. Springer, Berlin, pp 81-92
22. SM Galbraith GJ Rustin MA Lodge NJ Taylor JJ Stirling M Jameson P Thompson D Hough L Gumbrell AR Padhani 2002 Effects of 5,6-dimethylxanthane-4- acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging J Clin Oncol 20 18 3826 3840 12228202 10.1200/JCO.2002.09.144 1:CAS:528:DC%2BD38XntVyns7g%3D
23. JE Evelhoch PM LoRusso Z He Z DelProposto L Polin TH Corbett P Langmuir C Wheeler A Stone J Leadbetter AJ Ran DC Blakey JC Waterton 2004 Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126 Clin Cancer Res 10 3650 3657 15173071 10.1158/1078-0432.CCR-03-0417 1:CAS:528:DC%2BD2cXksVKnsbo%3D (Pubitemid 38697598)
24. SM Galbraith RJ Maxwell MA Lodge GM Tozer J Wilson NJ Taylor JJ Stirling L Sena AR Padhani GJS Rustin 2003 Combrestatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging J Clin Oncol 21 15 2831 2842 12807936 10.1200/JCO.2003.05.187 1:CAS:528:DC%2BD2cXpsVKjsb8%3D (Pubitemid 46621830)
25. Brown H, Prescott R (1999) Applied mixed models in medicine. Wiley, Chichester
26. Galbraith SM (2006) Imaging the effects of vasculature-targeting agents. In: Siemann DW (ed.) Vascular-targeted therapies in oncology. Wiley, Chichester, pp 277-304
27. MM Oken RH Creech DC Tormey J Horton TE Davis ET McFadden PP Carbone 1982 Toxicity and response criteria of the eastern cooperative oncology group Am J Clin Oncol 5 649 655 7165009 10.1097/00000421-198212000-00014 1:STN:280:DyaL3s7kvFOgsw%3D%3D (Pubitemid 13149996)
28. 1-weighted dynamic contrast-enhanced MRI. In: Jackson A, Buckley DL, Parker GJM (eds) Dynamic contrast-enhanced magnetic resonance imaging in oncology. Springer, Berlin, pp 69-80
29. GJM Parker C Roberts A Macdonald GA Buonaccorsi S Cheung DL Buckley A Jackson Y Watson K Davies GC Jayson 2006 Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI Magn Reson Med 56 993 1000 17036301 10.1002/mrm.21066 (Pubitemid 44691341)
30. MR Orton JA d'Arcy S Walker-Samuel DJ Hawkes D Atkinson DJ Collins MO Leach 2008 Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI Phy Med Biol 53 1225 1239 10.1088/0031-9155/53/5/005 (Pubitemid 351594423)
31. V Schmid B Whitcher AR Padhani NJ Taylor GZ Yang 2006 Bayesian methods for pharmacokinetic models in dynamic contrast-enhanced magnetic resonance imaging IEEE Trans Med Imaging 25 12 1627 1636 17167997 10.1109/TMI.2006.884210 (Pubitemid 44936711)
32. Whitcher B, Schmid VJ (2010) dcemriS4: a package for medical image analysis. R package version 0.40
33. R Development Core Team (2010) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0
34. Gilks WR, Richardson S, Spiegelhalter DJ (1996) Markov chain Monte Carlo in practice. Chapman & Hall, London
35. H Gudbjartsson S Patz 1995 The Rician distribution of noisy MRI data Magn Reson Med 34 910 914 8598820 10.1002/mrm.1910340618 1:STN:280: DyaK287mslKqtQ%3D%3D
36. MR Orton DJ Collins S Walker-Samuel JA d'Arcy DJ Hawkes D Atkinson MO Leach 2007 Bayesian estimation of pharmacokinetic parameters for DCE-MRI with a robust treatment of enhancement onset time Phy Med Biol 52 2393 2408 10.1088/0031-9155/52/9/005 (Pubitemid 46778516)
37. Collins DJ, Padhani AR (2004) Dynamic magnetic resonance imaging of tumor perfusion. IEEE Eng Biol Med Magazine 65-83
38. del Campo JM, Sebastian P, Hitt R, Carracedo C, Lokanatha D, Bourhis J, Harrington K, Midwinter D, El Hariry I, Biswas-Baldwin N (2008) Effect of lapatinib monotherapy on apoptosis and proliferation: results of a phase II randomised study in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 19(Suppl. 8):viii217-viii224. Abstract 6880